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A B S T R A C T
Angiotensin converting enzyme (ACE) inhibitory peptides from egg have demonstrated re-
duction of blood pressure (BP) in vivo. In this study we evaluated the effects of egg white
hydrolysate (EWH) prepared by thermolysin and pepsin in spontaneously hypertensive rats
(SHRs). Fourteen to sixteen week old SHRs were implanted with telemetry devices. After re-
covery, the rats were divided randomly into three groups: untreated, EWH low dose
(250 mg/kg BW), and EWH high dose (1000 mg/kg BW) for 12 days. BP showed a significant
reduction in the EWH high dose group compared to untreated controls. BP reduction was
associated with enhanced ex vivo vasodilation reduced oxidative/nitrosative stress, reduced
angiotensin converting enzyme and angiotensin II type 1 receptor expression, while en-
hanced angiotensin II type 2 receptor expression. Circulating level of angiotensin II was
unaffected. Thus, EWH exerted anti-hypertensive effects in SHRs through multiple mecha-
nisms of vascular relaxation and RAS modulation.
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1. Introduction
Hypertension, the persistent elevation of blood pressure (BP)
over 140/90 mm Hg, is associated with an increased risk of car-
diovascular diseases and is a growing health problemworldwide
(Chockalingam, 2008; Danaei et al., 2013). A number of under-
lying mechanisms, including hyperactivity of the renin–
angiotensin system (RAS), inflammation, oxidative stress and
impaired nitric oxide generation, contribute to the pathogen-
esis of hypertension.While a number of pharmaceutical anti-
hypertensives are currently available for clinical usage, many
are known to have significant side-effects in a disease that re-
quires lifelong therapy (Khanna, Lefkowitz, & White, 2008).
Moreover, some cases of hypertension are not adequately con-
trolled by commonly used pharmaceutical agents (Viera, 2012).
Hence, there has been a growing interest in developing novel
therapies for hypertension from natural sources.
Food derived proteins and peptides are a major source of
bioactive compounds with potential therapeutic applications
(Aluko, 2015; Balti et al., 2012; Girgih, Alashi, He, Malomo, &
Aluko, 2014; Saiga-Egusa, Iwai, Hayakawa, Takahata, &
Morimatsu, 2009). Egg is an inexpensive and nutritious source
of many proteins which can be used to generate novel bioactive
peptides. Our previous research has identified three peptides
IRW (Ile-Arg-Trp), IQW (Ile-Gln-Trp) and LKP (Leu-Lys-Pro) from
ovotransferrin hydrolysate (prepared by thermolysin and pepsin)
with anti-inflammatory, antioxidant and angiotensin convert-
ing enzyme (ACE) inhibitor properties (Majumder et al., 2013,
2015; Majumder & Wu, 2011). Indeed, these peptides showed
potent BP lowering effects in spontaneously hypertensive rats
(SHRs), a well-known animal model of hypertension (Dornas
& Silva, 2011). The isolation of specific proteins like
ovotransferrin from egg white as well as using individual
bioactive peptides derived from this isolated protein is expen-
sive. Hence, there is a greater feasibility associated with using
enzymatic hydrolysates of whole egg white (instead of the con-
stituent proteins or peptides) for therapeutic applications. It
is not known if egg white hydrolysate (EWH), as a source of
ovotransferrin with in vitro ACE-inhibitory activity, would also
exert antihypertensive effects in vivo. Given this background,
we fed EWH (generated by thermolysin and pepsin) orally to
SHRs to evaluate its potential as an anti-hypertensive treat-
ment and examine the mechanisms of action focusing on
various aspects of the RAS.
2. Materials and methods
2.1. Preparation of egg white hydrolysate
Hydrolysis of egg white was carried out as described previ-
ously (Majumder &Wu, 2011). Briefly, egg white slurry (5%, w/v)
was first heated to 80 °C for 10 min and digested with
thermoase PC10F (Amano Enzyme Inc. Nagoya, Japan) 0.1% w/w
at pH 8 and 65 °C for 90 min. The pH was then adjusted to
2.5 for pepsin digestion. Pepsin (from porcine stomach,
10,000 units/mg, American Laboratories Inc. Omaha, NE, USA)
was added at 1% w/w to the mixture at 55 °C and hydrolysis
was carried out for another 180 min. After heat inactivation
of enzymes, the hydrolysate was centrifuged and superna-
tant was collected and freeze dried for further experiments.
The average protein content of the hydrolysate was 77.69%.
2.2. Ethics statement, animal model and experimental
design
Rat experimental procedures were approved by the Univer-
sity of Alberta Animal Welfare Committee (Protocol # 611/09/
10D) in accordance with the guidelines issued by the Canadian
Council on Animal Care and also adhered to the Guide for the
Care and Use of Laboratory Animals published by the United
States National Institutes of Health. The feeding experiments
were carried out using fourteen to sixteen week old male spon-
taneous hypertensive rats (SHRs) weighing 290.0 ± 10.5 g
obtained from Charles River (Senneville, QC, Canada). Upon
arrival, rats were acclimatized for one week at the University
of Alberta animal facility with a 12:12 hour cycle of light:dark
in a humidity and temperature controlled (60% RH, and 23 °C)
environment and maintained on standard chow and water ad
libitum. After one-week acclimation, SHRs were chronically im-
planted with DSI telemetry transmitters (PA-C40; Data Sciences
International, Minneapolis, MN) as described previously
(Majumder et al., 2013). After one week recovery following
surgery, rats were randomly assigned into 3 groups (n = 6–7):
untreated (control), EWH low dose (250 mg/kg BW) and EWH
high dose (1000 mg/kg BW). EWH dosages were chosen based
on the previous studies done in our lab (Jahandideh et al., 2014).
Treatments were given orally once a day for 12 days after mixing
with 20 mL of Ensure (Abbott Nutrition, QC, Canada). Ensure
was used to enhance the palatability of the hydrolysate. The
untreated group received the same volume of Ensure only
(Jahandideh et al., 2014). BP was recorded on days 0 (base-
line), 3, 6, 9, and 12 for 24 h (10 s of every 1 min) for all animals.
On the morning of day 13, the animals were euthanized by ex-
sanguination via excision of the heart under inhaled isoflurane
anesthesia (isoflurane/oxygen; 1.0–2.5%mixture). Following sac-
rifice, blood was collected from the heart in EDTA coated tubes
(BDVacutainer, NJ, USA), and centrifuged (1000 g for 20 min at
4 °C) to obtain plasma. Tissues were removed immediately,
rinsed with cold saline, weighed, flash frozen with liquid ni-
trogen and stored at −80 °C for further analysis.The mesenteric
arteries were isolated immediately and used for ex vivo vas-
cular function studies.
2.3. Data acquisition and signal processing
Chronic measurement of BP was done in a quiet room with
minimal electrical interference as previously described
(Jahandideh et al., 2014). Mean arterial blood pressure (MAP)
was measured while systolic blood pressure (SBP) and dia-
stolic blood pressure (DBP) were extracted from the observed
signal. Heart rate (HR) was calculated between two consecu-
tive points and expressed in beats per minute (bpm).
2.4. Vascular function studies
Second order branches of the mesenteric arteries were care-
fully excised from SHRs and used for ex vivo vascular function
experiments. Isolation,mounting, normalization and validating
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integrity of vessels were the same as described before
(Jahandideh et al., 2014). Constrictor responses of vessels were
determined by assessing responses to phenylephrine (PE, 10−8
to 10−4 M, SigmaAldrich, Oakville, Canada). In two sets of vessels,
the role of nitric oxide (NO) in endothelium-dependent relax-
ation was assessed via studying the methacholine (MCh, 10−10
to 10−4 M, Sigma) relaxation response of vessels in the pres-
ence or absence of the nitric oxide synthase (NOS) inhibitor
N-nitro-L-arginine methyl ester (L-NAME, 100 µM, Sigma). The
contribution of vascular smooth muscle to relaxation was also
assessed in a separate set of vessels through studying the re-
laxation response of vessels to sodium nitroprusside (SNP, 10−10
to 10−5 M, Sigma); which is an endothelium-independent re-
laxing agent. At the end of the experiment, the vessels were
exposed to high potassium buffer to confirm their viability.
Vessels with constriction less than 80% of their maximum con-
striction to PE were excluded from analysis.
2.5. Plasma analysis for circulating Ang II
Plasma concentrations of angiotensin II (Ang II) were quanti-
fied by ELISA kit (Ang II ELISA, Cayman Chemical, Ann Arbor,
MI, USA) based on the manufacturer’s instructions.
2.6. Immunofluorescence
Aortic specimens were embedded in Tissue-Tek O.C.T Com-
pound (Sakura Finetek Europe, Zoeterwoude,The Netherlands)
and frozen immediately in liquid nitrogen for subsequent analy-
sis.Ten micrometer tissue sections were prepared, fixed in cold
acetone and incubated with blocking buffer (1% BSA in
phosphate-buffer saline) for 1 hour. The sections were then
immunostained overnight at 4 °C with rabbit polyclonal anti-
bodies for nitrotyrosine (Dilution 1:200; Chemicon, Temecula,
CA, USA), ACE, ACE2, angiotensin II type 1 (AT1R) and type 2
receptor (AT2R) (Dilution 1:200; Santa Cruz Biotechnology, Santa
Cruz, CA, USA). Incubation with a secondary antibody (dilu-
tion 1:500; Alexa Fluor 546 (red), Invitrogen, Burlington, ON,
Canada) was performed for 30 min in the dark at room tem-
perature. For nitrotyrosine, glass cover-slips were mounted with
a Vectashield H-1200 Mounting Kit, containing nuclear stain,
DAPI (Vector Laboratories, Burlington, ON, Canada) on the cor-
responding slides and immediately visualized under an
Olympus IX81 fluorescencemicroscope (Olympus,Tokyo, Japan).
Images were obtained using SlideBook imaging software
(Olympus) and presented at 100× magnification. For ACE, ACE2,
AT1R and AT2R, glass cover-slips were mounted with PBS and
scanned by Odyssey Sa system (Licor Biosciences) with 20 µm
resolution. A control image with the secondary antibody alone
was used to detect any nonspecific binding. The images were
then quantified by subtracting the background fluorescence in
the control image, so only the fluorescence from specific
immunostaining was visible.
2.7. Statistical analysis
All data presented are mean ± SEM of 4–7 experiments, as in-
dicated in the figure legends. MCh curves were fitted using
nonlinear regression, and values for area under the curve (AUC)
were compared. Statistical analysis was performed using
GraphPad Prism software (version 6.0). For analyses of BP data,
we used a two-way analysis of variance (ANOVA) with Tukey’s
post-hoc test. For all other studies, a t-test was used for com-
parison between 2 groups while a one-way ANOVA (with
Dunnett’s post-hoc test) was performed for comparison in-
volving 3 or more groups. A p-value <0.05 was considered
statistically significant.
3. Results and discussion
3.1. EWH reduces BP in SHRs
Baseline MAP in all experimental groups was above 160 mmHg;
which is an indication of hypertension in SHRs. The patho-
genesis of hypertension in SHRs is similar to human essential
hypertension (Okamoto & Aoki, 1963). In this study, although
both doses of EWH tended to reduce BP in SHRs over the ex-
perimental period compared to the untreated group, this
reduction was only significant in the high dose treated group
(1000 mg/kg BW) (p < 0.001, Fig. 1A–C). HR was not different
between the groups (Fig. 1D). Hydrolysis of egg white breaks
down the protein structure generating bioactive peptides and
possibly free amino acids which may be critical for the anti-
hypertensive effects. Hydrolysis of the egg white with
thermolysin and pepsin generated a complex array of pep-
tides which could potentially contribute to the observed
antihypertensive effects. The hypotensive effects of egg-
derived peptides have been reported in the literature (Duan
et al., 2014; Jahandideh et al., 2014; Majumder et al., 2013;
Matoba, Usui, Fujita, & Yoshikawa, 1999; Miguel, Lopez-Fandino,
Ramos, & Aleixandre, 2005; Rawendra et al., 2013; Yu, Zhao,
Liu, Lu, & Chen, 2011). Interestingly, the presence of tripeptides
IRW, IQW, LKP with proven antihypertensive properties has also
been confirmed in our EWH preparation through LC–MS/MS
analysis (data not shown). Utilizing protein hydrolysates instead
of single peptides has the advantage of reduced cost of pro-
cessing and easier incorporation into food system as a natural
component. Moreover, the available peptides in the whole
protein hydrolysate may have other beneficial biological ac-
tivities. Since the BP was only significantly changed in high dose
EWH treated animals, all the subsequent experiments were
carried out on this group compared to untreated group.
3.2. EWH improves vascular relaxation, reduces
nitrosative stress and modifies Ang II receptors expression
SHRs show impaired vasodilation, higher circulating levels of
Ang II as well as increases in oxidative stress and inflamma-
tion compared to normal rats (Zicha & Kunes, 1999).The effect
of EWH on vascular function in SHRs was evaluated as one of
the possible mechanisms for its antihypertensive effects. Since
mesenteric arteries contribute significantly to the alteration
of BP through affecting systemic vascular resistance
(Pannirselvam, Wiehler, Anderson, & Triggle, 2005), this vas-
cular bed was studied to investigate the effects of the treatment
on ex vivo vascular function. As evident in Fig. 2A, vasodila-
tion to MCh was significantly enhanced by treatment with EWH
compared to the untreated group (p < 0.05). Enhanced NO is
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one of the possible endothelium-dependent mechanisms of va-
sodilation. Incubation of mesenteric arteries with L-NAME, a
NOS inhibitor, reduced vasodilation in both untreated and EWH
treated animals (Fig. 2B and C), suggesting a contribution of
NO to relaxation in both groups. However, EWH further en-
hanced NO-dependent vasodilation compared to the untreated
group as shown by a significant increase in the delta area under
the curve (Δ AUC) of the MCh curves obtained for each of the
two groups with and without NOS inhibition (p < 0.05, Fig. 2D).
This increase in NO-dependent vasodilation may be due to the
enhanced NO bioavailability through scavenging of free radi-
cals or increased NO production in the vasculature. Vascular
relaxation to SNP, an exogenous NO donor, was also signifi-
cantly enhanced in EWH treated group compared to the
untreated group (p < 0.05, Fig. 3); but to a lesser extent than
MCh responses. This implies the involvement of either
endothelium-independent mechanisms (in addition to
endothelium-dependent ones) or enhanced NO bioavailability
in EWH treated compared to untreated group.When the effect
of EWH treatment on nitrosative stress in aortic sections of SHRs
was further studied, we observed a significant decrease in aortic
nitrotyrosine staining in EWH treated animals (p < 0.01, Fig. 4).
This may explain the improved NO bioavailability and vaso-
dilation effects observed in the vascular function experiments.
Ang II, the principal component of the RAS pathway, has
diverse physiological actions regulating blood pressure and salt/
water balance; elevated circulating Ang II level leads to high
BP in SHR. Since EWH was initially identified as an in vitro ACE
inhibitor, plasma Ang II levels were assessed in both EWH and
untreated animals. Plasma Ang II levels were not signifi-
cantly different between EWH and untreated groups (p > 0.05,
Fig. 5), indicating that EWH may not work solely as an ACE in-
hibitor in reducing BP in SHRs. However, ACE expression in the
EWH treated animals was significantly reduced compared to
the untreated animals (p < 0.05, Fig. 6A). ACE2 is another con-
tributor to Ang II plasma level; however feeding EWH did not
affect the expression level of ACE2 (p > 0.05, Fig. 6B).
We further assessed the expression level of Ang II recep-
tors. Ang II acts through two main receptors, angiotensin type
1 and type 2 receptors. Binding to AT1R receptor causes vaso-
constriction in vascular smooth muscle cells and other
potentially harmful consequences while binding to AT2R re-
ceptor induces opposing effects (Balakumar & Jagadeesh, 2014).
Interestingly, EWH significantly reduced the expression of AT1R
and enhanced concomitantly that of AT2R in SHRs compared
to the untreated group (p < 0.05, Fig. 7A and B). Since the AT1R
is responsible for the most known pathogenic effects of Ang
II in the body, this finding offers a potentially novel way to
Fig. 1 – Egg white hydrolysate (EWH) reduces BP in SHRs. (A, B, and C) MAP, SBP, and DBP (mmHg) values for untreated or
EWH treated (250 and 1000 mg/kg BW) SHRs over a period of 12 days. BP values for each represent the mean BP recorded
over a 24 hr period. (D) HR (bpm) of SHRs in treatment groups over 12 days. Treatment with EWH (1000 mg/kg BW)
significantly lowered MAP (A), SBP (B), and DBP (C) but not heart rate (D). Data represented as mean ± SEM from n = 6–7
animals per treatment group. * indicates p < 0.05 and ** indicates p < 0.01 compared to untreated group. NS indicates not
significant compared to the untreated group.
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attenuate the effect of an overactive RAS pathway. This ben-
eficial effect was further enhanced by increased AT2R
expression, contributed collectively to improved vasodilation
in vascular function experiments. Therefore, although rats in
the EWH and untreated groups had almost the same levels of
circulating Ang II, the antihypertensive effects observed upon
EWH feeding were due mainly to different expression levels
of Ang II receptors. It is possible that the EWH treatment in-
creases the breakdown of receptor protein and/or reduces the
protein synthesis of the receptor. To the best of our knowl-
edge, this is the first study reporting the effects of a food
compound on modulating AT1R and AT2R expression in vivo.
Fig. 2 – EWH treatment induces nitric oxide contribution to vasodilation in mesenteric arteries of SHRs. (A) EWH
(1000 mg/kg BW) significantly increased vasorelaxation to MCh. Pre-incubation with L-NAME (100 µM) reduced
vasorelaxation in untreated rats (B) as well as EWH treated rats (C). EWH further enhanced NO dependent vasorelaxation
compared to untreated group (D). Data represented as mean ± SEM from n = 4–6 animals per treatment group. * indicates
p < 0.05 compared to untreated group.
Fig. 3 – EWH treatment enhances vasodilation in the presence of exogenous nitric oxide in mesenteric arteries of SHRs.
EWH (1000 mg/kg BW) significantly increased vasorelaxation to SNP in SHRs. Data represented as mean ± SEM from n = 4–7
animals per treatment group. * indicates p < 0.05 compared to untreated group.
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Since BP is regulated by several organs in the body and is
sex-specific, using only male SHRs and lack of normotensive
control rats is one of the limitations of our study. The effects
of EWH on sympathetic nervous system through binding to
opioid receptors remain to be answered in future studies. It
is also interesting to investigate the effects of EWH on BP post
treatment to see if the effect on BP remains or not. As a well-
known food allergy, the possible allergenicity of EWH especially
in subjects already allergic to egg and egg products also needs
to be evaluated in future studies.
4. Conclusion
The present study demonstrated the role of EWH in reducing
BP in SHRs through several mechanisms. The reduction in BP
was concomitant with an increased vasodilation, reduced
nitrosative stress, reduced ACE and AT1R expression, as well
as enhanced AT2R expression. While our findings are novel,
further research is needed to ascertain the role of EWH
on mechanisms involved in endothelial independent
vasorelaxation to achieve a comprehensive understanding of
underlying mechanisms.The findings from this study may es-
tablish the potential of egg derived bioactive peptides in the
management of hypertension and associated complications.
Acknowledgement
This research was funded by grants fromAlberta Livestock and
Meat Agency (ALMA), Egg Farmers of Canada, Egg Farmers of
Alberta, and Natural Sciences and Engineering Research Council
(NSERC) of Canada to J. Wu. S. T. Davidge is a Canada Re-
search Chair in Maternal and Fetal Cardiovascular Health and
the Davidge laboratory is supported by the Women and Chil-
dren’s Health Research Institute (WCHRI) and grants from the
Canadian Institutes of Health Research (CIHR).The funders had
no role in study design, data collection and analysis, decision
to publish or preparation of the manuscript.We would like to
thank Ms. Anita Quon for her technical assistance.
Fig. 4 – EWH treatment reduces tissue nitrotyrosine in
SHRs. Immunostaining for nitrotyrosine in aortic sections
of untreated and EWH (1000 mg/kg BW) treated SHRs. Data
represented as mean ± SEM from n = 4 animals per
treatment group. ** indicates p < 0.01 compared to
untreated group.
Fig. 5 – Effects of EWH on plasma circulatory Ang II. Ang II
level was not affected after 12 days of treatment with EWH
(1000 mg/kg BW). Data represented as mean ± SEM from
n = 4 animals per treatment group.
Fig. 6 – EWH reduces ACE but not ACE2 expression in aorta
of SHRs. Immunostaining for ACE (A) and ACE2 (B) in aortic
sections from untreated and EWH (1000 mg/kg BW) treated
SHRs. Data represented as mean ± SEM from n = 4 animals
per treatment group. * indicates p < 0.05 compared to
untreated group.
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